Remus Pharmaceuticals Limited — Board Meeting, 10-11-2025: Outcome of Board Meeting

Remus Pharmaceuticals' Board approved H1 FY26 consolidated financial results: PAT at ₹17.50 Cr (up 33.97%) and revenue at ₹400.20 Cr (up 46.80%). The board declared an interim dividend of ₹0.50 per share (record date Nov 14, 2025) and approved a postal ballot notice, alongside strategic market entries and new product launches.